Targeting Inflammation Using Salsalate in CardioVascular Disease

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (107 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: placebocoronarysubjectscarcinomasquamous cell
  Phrases that lowered it: participantsalzheimernormalmaledementia
• Sponsor's past termination rate: 33.3% (raises risk) · Sponsor's track record
• Primary purpose: prevention (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 3 (lowers risk) · Design
• Minimum age: 21 (lowers risk) · Who can join
• Has a data monitoring committee: Yes (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Phase: 2/3 (raises risk) · Design
• Sponsor's past trials: 6 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 6.6% (lowers risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 71.5% (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Keywords listed: 5 (lowers risk) · Design
• Drug's FAERS reports before start: 228 (lowers risk) · Drug's FDA history
• Maximum age: 75 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II NCT00799643 · started 2008 · scored riskier than 78% of active trials completed
• Inflammation Inhibition in Prediabetic Humans NCT01977417 · started 2012 · scored riskier than 17% of active trials terminated
• A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia NCT02166814 · started 2014 · scored riskier than 11% of active trials completed
• YN001-004 in Patients With Coronary Atherosclerosis in Australia NCT06700720 · started 2026 · scored riskier than 50% of active trials terminated
• Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease NCT01609582 · started 2012 · scored riskier than 83% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.